A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Marguerite RoAD
- Sponsors Chugai Pharmaceutical; Roche
- 16 Apr 2018 According to the Genentech media release, data from this study will be presented in a platform session at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.
- 26 Mar 2018 Planned End Date changed from 23 Jul 2020 to 20 Nov 2020.
- 26 Mar 2018 Planned primary completion date changed from 23 Jul 2020 to 13 Apr 2018.